The lethal K18-hACE2 knock-in mouse model mimicking the severe pneumonia of COVID-19 is practicable for antiviral development

References

• Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579(7798):265–269. doi:10.1038/s41586-020-2008-3
   PubMed Web of Science ®Google Scholar
• Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–733. doi:10.1056/NEJMoa2001017
   PubMed Web of Science ®Google Scholar
• Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270–273. doi:10.1038/s41586-020-2012-7
   PubMed Web of Science ®Google Scholar
• Chen Y, Liu QY, Guo DY. Emerging coronaviruses: Genome structure, replication, and pathogenesis. J Med Virol. 2020;92(4):418–423. doi:10.1002/jmv.25681
   PubMed Web of Science ®Google Scholar
• Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–513. doi:10.1016/S0140-6736(20)30211-7
   PubMed Web of Science ®Google Scholar
• Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382(18):1708–1720. doi:10.1056/NEJMoa2002032
   PubMed Web of Science ®Google Scholar
• Morse JS, Lalonde T, Xu S, et al. Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019-nCoV. Chembiochem. 2020;21(5):730–738. doi:10.1002/cbic.202000047
   PubMed Web of Science ®Google Scholar
• Tian S, Xiong Y, Liu H, et al. Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies. Mod Pathol. 2020;33(6):1007–1014. doi:10.1038/s41379-020-0536-x
   PubMed Web of Science ®Google Scholar
• Schaller T, Hirschbuhl K, Burkhardt K, et al. Postmortem examination of patients with COVID-19. JAMA. 2020;323(24):2518–2520. doi:10.1001/jama.2020.8907
   PubMed Web of Science ®Google Scholar
• Edler C, Schroder AS, Aepfelbacher M, et al. Dying with SARS-CoV-2 infection-an autopsy study of the first consecutive 80 cases in Hamburg, Germany. Int J Legal Med. 2020;134(4):1275–1284. doi:10.1007/s00414-020-02317-w
   PubMed Web of Science ®Google Scholar
• Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. doi:10.1016/S0140-6736(20)30183-5
   PubMed Web of Science ®Google Scholar
• Sia SF, Yan LM, Chin AWH, et al. Pathogenesis and transmission of SARS-CoV-2 in golden hamsters. Nature. 2020;583(7818):834–838. doi:10.1038/s41586-020-2342-5
   PubMed Web of Science ®Google Scholar
• Imai M, Iwatsuki-Horimoto K, Hatta M, et al. Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development. Proc Natl Acad Sci U S A. 2020;117(28):16587–16595. doi:10.1073/pnas.2009799117
   PubMed Web of Science ®Google Scholar
• Hu Y, Liu M, Qin H, et al. Artemether, Artesunate, Arteannuin B, Echinatin, Licochalcone B and Andrographolide Effectively Inhibit SARS-CoV-2 and Related Viruses In Vitro. Front Cell Infect Microbiol. 2021;11:680127. doi:10.3389/fcimb.2021.680127
   PubMed Web of Science ®Google Scholar
• Xu L, Yu DD, Ma YH, et al. COVID-19-like symptoms observed in Chinese tree shrews infected with SARS-CoV-2. Zool Res. 2020;41(5):517–526. doi:10.24272/j.issn.2095-8137.2020.053
   PubMed Web of Science ®Google Scholar
• Woolsey C, Borisevich V, Prasad AN, et al. Establishment of an African green monkey model for COVID-19 and protection against re-infection. Nat Immunol. 2021;22(1):86–98. doi:10.1038/s41590-020-00835-8
   PubMed Web of Science ®Google Scholar
• Rockx B, Kuiken T, Herfst S, et al. Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model. Science. 2020;368(6494):1012–1015. doi:10.1126/science.abb7314
   PubMed Web of Science ®Google Scholar
• Shang J, Ye G, Shi K, et al. Structural basis of receptor recognition by SARS-CoV-2. Nature. 2020;581(7807):221–224. doi:10.1038/s41586-020-2179-y
   PubMed Web of Science ®Google Scholar
• Israelow B, Song E, Mao T, et al. Mouse model of SARS-CoV-2 reveals inflammatory role of type I interferon signaling. J Exp Med. 2020;217(12. doi:10.1084/jem.20201241
   PubMed Web of Science ®Google Scholar
• Rathnasinghe R, Strohmeier S, Amanat F, et al. Comparison of transgenic and adenovirus hACE2 mouse models for SARS-CoV-2 infection. Emerg Microbes Infect. 2020;9(1):2433–2445. doi:10.1080/22221751.2020.1838955
   PubMed Web of Science ®Google Scholar
• Zheng J, Wong LR, Li K, et al. COVID-19 treatments and pathogenesis including anosmia in K18-hACE2 mice. Nature. 2021;589(7843):603–607. doi:10.1038/s41586-020-2943-z
   PubMed Web of Science ®Google Scholar
• Moreau GB, Burgess SL, Sturek JM, et al. Evaluation of K18-hACE2 Mice as a Model of SARS-CoV-2 Infection. Am J Trop Med Hyg. 2020;103(3):1215–1219. doi:10.4269/ajtmh.20-0762
   PubMed Web of Science ®Google Scholar
• Liu X, Zaid A, Freitas JR, et al. Infectious clones produce SARS-CoV-2 that causes severe pulmonary disease in infected K18-human ACE2 mice. mBio. 2021;12(2.
   Web of Science ®Google Scholar
• Yinda CK, Port JR, Bushmaker T, et al. K18-hACE2 mice develop respiratory disease resembling severe COVID-19. PLoS Pathog. 2021;17(1):e1009195. doi:10.1371/journal.ppat.1009195
   PubMed Web of Science ®Google Scholar
• Jiang RD, Liu MQ, Chen Y, et al. Pathogenesis of SARS-CoV-2 in transgenic mice expressing human angiotensin-converting enzyme 2. Cell. 2020;182(1):50–58.e8. doi:10.1016/j.cell.2020.05.027
   PubMed Web of Science ®Google Scholar
• Golden JW, Cline CR, Zeng X, et al. Human angiotensin-converting enzyme 2 transgenic mice infected with SARS-CoV-2 develop severe and fatal respiratory disease. JCI Insight. 2020;5(19. doi:10.1172/jci.insight.142032
   PubMed Web of Science ®Google Scholar
• Winkler ES, Bailey AL, Kafai NM, et al. SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function. Nature Immunol. 2020;21(11):1327–1335. doi:10.1038/s41590-020-0778-2
   PubMed Web of Science ®Google Scholar
• Oladunni FS, Park JG, Pino PA, et al. Lethality of SARS-CoV-2 infection in K18 human angiotensin-converting enzyme 2 transgenic mice. Nat Commun. 2020;11(1):6122. doi:10.1038/s41467-020-19891-7
   PubMed Web of Science ®Google Scholar
• Song E, Zhang C, Israelow B, et al. Neuroinvasion of SARS-CoV-2 in human and mouse brain. J Exp Med. 2021;218(3. doi:10.1084/jem.20202135
   Web of Science ®Google Scholar
• Kumari P, Rothan HA, Natekar JP, et al. Neuroinvasion and Encephalitis Following Intranasal Inoculation of SARS-CoV-2 in K18-hACE2 Mice. Viruses. 2021;13(1):132. doi:10.3390/v13010132
   PubMed Web of Science ®Google Scholar
• Golden JW, Zeng X, Cline CR, et al. Human convalescent plasma protects K18-hACE2 mice against severe respiratory disease. J Gen Virol. 2021;102(5). doi:10.1099/jgv.0.001599
   PubMed Web of Science ®Google Scholar
• Caceres CJ, Cardenas-Garcia S, Carnaccini S, et al. Efficacy of GC-376 against SARS-CoV-2 virus infection in the K18 hACE2 transgenic mouse model. Sci Rep. 2021;11(1):9609. doi:10.1038/s41598-021-89013-w
   PubMed Web of Science ®Google Scholar
• Sun SH, Chen Q, Gu HJ, et al. A mouse model of SARS-CoV-2 infection and pathogenesis. Cell Host Microbe. 2020;28(1):124–133.e4. doi:10.1016/j.chom.2020.05.020
   PubMed Web of Science ®Google Scholar
• Bao L, Deng W, Huang B, et al. The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. Nature. 2020;583(7818):830–833. doi:10.1038/s41586-020-2312-y
   PubMed Web of Science ®Google Scholar
• Dinnon KH, 3rd, Leist SR, Schafer A, et al. A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures. Nature. 2020;586(7830):560–566. doi:10.1038/s41586-020-2708-8
   PubMed Web of Science ®Google Scholar
• Gu H, Chen Q, Yang G, et al. Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy. Science. 2020;369(6511):1603–1607. doi:10.1126/science.abc4730
   PubMed Web of Science ®Google Scholar
• Sun S, Gu H, Cao L, et al. Characterization and structural basis of a lethal mouse-adapted SARS-CoV-2. Nat Commun. 2021;12(1):5654. doi:10.1038/s41467-021-25903-x
   PubMed Web of Science ®Google Scholar
• Leist SR, Dinnon KH, 3rd, Schafer A, et al. A mouse-adapted SARS-CoV-2 induces acute lung injury and mortality in standard laboratory mice. Cell. 2020;183(4):1070–1085.e12. doi:10.1016/j.cell.2020.09.050
   PubMed Web of Science ®Google Scholar
• McCray PB, Jr., Pewe L, Wohlford-Lenane C, et al. Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus. J Virol. 2007;81(2):813–821. doi:10.1128/JVI.02012-06
   PubMed Web of Science ®Google Scholar
• Gan ES, Syenina A, Linster M, et al. A mouse model of lethal respiratory dysfunction for SARS-CoV-2 infection. Antiviral Res. 2021;193:105138. doi:10.1016/j.antiviral.2021.105138
   PubMed Web of Science ®Google Scholar
• Abdelnabi R, Foo CS, Zhang X, et al. The omicron (B.1.1.529) SARS-CoV-2 variant of concern does not readily infect Syrian hamsters. Antiviral Res. 2022;198:105253. doi:10.1016/j.antiviral.2022.105253
   PubMed Web of Science ®Google Scholar
• Ying B, Scheaffer SM, Whitener B, et al. Boosting with variant-matched or historical mRNA vaccines protects against Omicron infection in mice. Cell. 2022;185(9):1572–1587.e11. doi:10.1016/j.cell.2022.03.037
   PubMed Web of Science ®Google Scholar
• Shuai HP, Chan JFW, Hu BJ, et al. Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron. Nature. 2022;603(7902):693–699. doi:10.1038/s41586-022-04442-5
   PubMed Web of Science ®Google Scholar
• Halfmann PJ, Iida S, Iwatsuki-Horimoto K, et al. SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters. Nature. 2022;603(7902):687–692. doi:10.1038/s41586-022-04441-6
   PubMed Web of Science ®Google Scholar
• Chen Y, Liu Q, Zhou L, et al. Emerging SARS-CoV-2 variants: Why, how, and what's next? Cell Insight. 2022;1(3):100029. doi:10.1016/j.cellin.2022.100029
   PubMedGoogle Scholar
• Zhang L, Zhou L, Bao L, et al. SARS-CoV-2 crosses the blood-brain barrier accompanied with basement membrane disruption without tight junctions alteration. Signal Transduct Target Ther. 2021;6(1):337. doi:10.1038/s41392-021-00719-9
   PubMed Web of Science ®Google Scholar
• Liu QY, Zhao HY, Li ZQ, et al. Broadly neutralizing antibodies derived from the earliest COVID-19 convalescents protect mice from SARS-CoV-2 variants challenge. Signal Transduction and Targeted Therapy. 2023;8:347. doi:10.1038/s41392-023-01615-0
   PubMed Web of Science ®Google Scholar
• Corbett KS, Edwards DK, Leist SR, et al. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature. 2020;586(7830):567–571. doi:10.1038/s41586-020-2622-0
   PubMed Web of Science ®Google Scholar
• Jeong JH, Chokkakula S, Min SC, et al. Combination therapy with nirmatrelvir and molnupiravir improves the survival of SARS-CoV-2 infected mice. Antiviral Res. 2022;208:105430. doi:10.1016/j.antiviral.2022.105430
   PubMed Web of Science ®Google Scholar
• Sun J, Zhuang Z, Zheng J, et al. Generation of a broadly useful model for COVID-19 pathogenesis, vaccination, and treatment. Cell. 2020;182(3):734–743.e5. doi:10.1016/j.cell.2020.06.010
   PubMed Web of Science ®Google Scholar
• Ueno M, Iwata-Yoshikawa N, Matsunaga A, et al. Isolation of human monoclonal antibodies with neutralizing activity to a broad spectrum of SARS-CoV-2 viruses including the Omicron variants. Antiviral Res. 2022;201:105297. doi:10.1016/j.antiviral.2022.105297
   PubMed Web of Science ®Google Scholar
• Baum A, Ajithdoss D, Copin R, et al. REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters. Science. 2020;370(6520):1110–1115. doi:10.1126/science.abe2402
   PubMed Web of Science ®Google Scholar
• Onodera T, Kita S, Adachi Y, et al. A SARS-CoV-2 antibody broadly neutralizes SARS-related coronaviruses and variants by coordinated recognition of a virus-vulnerable site. Immunity. 2021;54(10):2385–2398.e10. doi:10.1016/j.immuni.2021.08.025
   PubMed Web of Science ®Google Scholar
• Uraki R, Kiso M, Iida S, et al. Characterization and antiviral susceptibility ofSARS-CoV-2 Omicron BA.2. Nature. 2022;607(7917):119–127. doi:10.1038/s41586-022-04856-1
   PubMed Web of Science ®Google Scholar
• Najjar-Debbiny R, Gronich N, Weber G, et al. Effectiveness of Paxlovid in reducing severe coronavirus disease 2019 and mortality in high-risk patients. Clin Infect Dis. 2023;76(3):E342–E349. doi:10.1093/cid/ciac443
   PubMed Web of Science ®Google Scholar
• Spinner CD, Gottlieb RL, Criner GJ, et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19 a randomized clinical trial. JAMA. 2020;324(11):1110–1057. doi:10.1001/jama.2020.11856
   Web of Science ®Google Scholar
• Hikmet F, Méar L, Edvinsson Å, et al. The protein expression profile of ACE2 in human tissues. Mol Syst Biol. 2020;16(7). doi:10.15252/msb.20209610
   PubMed Web of Science ®Google Scholar
• Hamming I, Timens W, Bulthuis MLC, et al. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004;203(2):631–637. doi:10.1002/path.1570
   PubMed Web of Science ®Google Scholar
• Carson MJ, Doose JM, Melchior B, et al. CNS immune privilege: hiding in plain sight. Immunol Rev. 2006;213:48–65. doi:10.1111/j.1600-065X.2006.00441.x
   PubMed Web of Science ®Google Scholar
• Turrin NP, Rivest S. Molecular and cellular immune mediators of neuroprotection. Mol Neurobiol. 2006;34(3):221–242. doi:10.1385/MN:34:3:221
   PubMed Web of Science ®Google Scholar
• Ai L, Li Y, Zhou L, et al. Lyophilized mRNA-lipid nanoparticle vaccines with long-term stability and high antigenicity against SARS-CoV-2. Cell Discov. 2023;9(1):9. doi:10.1038/s41421-022-00517-9
   PubMed Web of Science ®Google Scholar